Scinopharm Taiwan, Ltd. AI Stock Analysis
Scinopharm Taiwan, Ltd. (1789) AI Stock Analysis
Scinopharm Taiwan, Ltd.
(TWSE:1789)
Scinopharm Taiwan scores in the middle of the range. Financial strength is genuine — an almost debt-free balance sheet and cash flow that comfortably exceeds reported earnings give the company real staying power — but it is offset by six years of flat revenue, a steep margin squeeze and a roughly 60% drop in net income that leaves return on equity at just 1.3%. Valuation compounds the concern, with a P/E near 898 driven by depressed earnings and only a 1.4% dividend yield. Technicals are the modest bright spot, with the price above its 20-, 50- and 100-day averages and a positive MACD, though it still trades below the 200-day average and momentum readings are only neutral-to-firm. Overall: low financial risk, but limited earnings momentum and a demanding valuation.
Scinopharm Taiwan, Ltd. (1789) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 15.66B
- Dividend Yield
- 1.43%
- Average Volume (3M)
- 525.24K
- Price to Earnings (P/E)
- 916.3
- Beta (1Y)
- 0.32
- Revenue Growth
- -4.75%
- EPS Growth
- -90.91%
- Country
- TW
- Employees
- 1,010
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Scinopharm Taiwan, Ltd. Business Overview & Revenue Model
Company Description
ScinoPharm Taiwan, Ltd., along with its subsidiaries, specializes in the research, development, production, and global distribution of cGMP-compliant active pharmaceutical ingredients (APIs). The company supplies these APIs to pharmaceutical clients...
Scinopharm Taiwan, Ltd. Financial Statement Overview
Summary
A fortress balance sheet (score 84) anchors the profile: equity funds nearly 89% of assets and debt-to-equity sits at just 0.07, leaving minimal financial risk. Cash flow is also respectable (66), with operating cash flow of NT$597 million running more than four times net income and free cash flow positive at NT$306 million, though both have declined year over year. The clear weak spot is the income statement (42): revenue has stagnated for six years and fell about 7% to NT$3.16 billion, while gross, operating and net margins all compressed sharply, cutting net income roughly 60% to NT$137 million and pushing return on equity to just 1.3%. Net result is a safe but under-earning business with little near-term profit momentum.
Income Statement
42NeutralBalance Sheet
84Very PositiveCash Flow
66Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.07B | 3.16B | 3.41B | 3.19B | 3.26B | 2.76B |
| Gross Profit | 877.39M | 1.10B | 1.30B | 1.22B | 1.25B | 1.28B |
| EBITDA | 512.79M | 673.97M | 909.38M | 819.15M | 885.34M | 690.37M |
| Net Income | 37.73M | 136.95M | 339.35M | 287.06M | 353.22M | 243.47M |
Balance Sheet | ||||||
| Total Assets | 12.36B | 11.86B | 11.94B | 11.72B | 11.91B | 11.69B |
| Cash, Cash Equivalents and Short-Term Investments | 3.50B | 3.11B | 4.17B | 3.95B | 4.35B | 4.13B |
| Total Debt | 873.09M | 762.67M | 676.75M | 621.10M | 677.91M | 557.60M |
| Total Liabilities | 1.90B | 1.33B | 1.42B | 1.36B | 1.46B | 1.18B |
| Stockholders Equity | 10.46B | 10.52B | 10.53B | 10.36B | 10.45B | 10.51B |
Cash Flow | ||||||
| Free Cash Flow | 576.85M | 305.82M | 462.18M | -53.59M | 523.75M | 188.50M |
| Operating Cash Flow | 805.65M | 597.11M | 750.91M | 231.13M | 773.79M | 509.82M |
| Investing Cash Flow | -229.22M | -1.45B | -293.38M | -233.29M | -253.62M | -69.98M |
| Financing Cash Flow | -210.75M | -203.50M | -244.89M | -340.98M | -314.83M | -412.77M |
Scinopharm Taiwan, Ltd. Peers Comparison
Overall Rating
TW:662070Outperform
TW:411461Neutral- TW:178957Neutral
TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6620 | 70Outperform | TWD 20.83B | 72.70 | ― | 1.65% | ― | ― |
| TW:4114 | 61Neutral | TWD 14.97B | 17.63 | ― | 3.05% | 11.40% | 9.36% |
| TW:1789 | 57Neutral | TWD 16.01B | 916.29 | ― | 1.43% | -4.75% | -90.91% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6547 | 40Underperform | TWD 16.94B | -408.17 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1789 | Scinopharm Taiwan, Ltd. | 20.25 | 2.75 | 15.70% | |
| TW:4114 | Synmosa Biopharma Corp | 27.85 | -1.93 | -6.48% | |
| TW:6547 | Medigen Vaccine Biologics Corp. | 51.50 | 14.00 | 37.33% | |
| TW:6586 | CHO Pharma, Inc. | 74.40 | 43.90 | 143.93% | |
| TW:6589 | EirGenix, Inc. | 51.40 | -16.40 | -24.19% | |
| TW:6620 | Handa Pharmaceuticals Inc | 125.50 | 6.46 | 5.43% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026